Jack Bendheim Sells 10,560 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 10,560 shares of the company’s stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $52.68, for a total value of $556,300.80. Following the completion of the sale, the chief executive officer owned 80,360 shares of the company’s stock, valued at approximately $4,233,364.80. This trade represents a 11.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jack Bendheim also recently made the following trade(s):

• On Thursday, March 19th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $52.52, for a total value of $369,740.80.
• On Tuesday, March 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.66, for a total transaction of $272,764.80.
• On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $48.91, for a total transaction of $258,244.80.
• On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $53.73, for a total transaction of $378,259.20.
• On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.37, for a total value of $361,644.80.
• On Friday, February 20th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.42, for a total value of $361,996.80.
• On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.40, for a total value of $361,856.00.
• On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.96, for a total value of $365,798.40.
• On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.62, for a total value of $732,178.08.
• On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.81, for a total value of $3,005,705.34.

Phibro Animal Health Trading Down 3.1%

Shares of PAHC opened at $50.76 on Friday. The business’s 50-day moving average price is $47.57 and its 200 day moving average price is $42.74. The company has a current ratio of 3.05, a quick ratio of 1.22 and a debt-to-equity ratio of 2.14. The stock has a market capitalization of $2.06 billion, a P/E ratio of 22.56, a P/E/G ratio of 0.80 and a beta of 0.74. Phibro Animal Health Corporation has a 1-year low of $16.16 and a 1-year high of $56.30.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.18. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. The company had revenue of $373.91 million during the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Analysts expect that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th will be issued a dividend of $0.12 per share. The ex-dividend date is Wednesday, March 4th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 0.9%. Phibro Animal Health’s payout ratio is currently 21.33%.

Hedge Funds Weigh In On Phibro Animal Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PAHC. Millennium Management LLC increased its stake in shares of Phibro Animal Health by 4,227.1% during the 4th quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock worth $23,959,000 after purchasing an additional 626,492 shares during the last quarter. Capricorn Fund Managers Ltd bought a new stake in Phibro Animal Health in the third quarter worth $10,233,000. JPMorgan Chase & Co. increased its position in Phibro Animal Health by 1,730.9% during the third quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock worth $9,634,000 after buying an additional 225,110 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in Phibro Animal Health during the third quarter valued at about $8,931,000. Finally, Ranger Investment Management L.P. raised its holdings in Phibro Animal Health by 101.1% during the second quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company’s stock valued at $9,143,000 after buying an additional 179,975 shares in the last quarter. Institutional investors own 99.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Morgan Stanley set a $49.00 price objective on shares of Phibro Animal Health in a research note on Friday, February 6th. Finally, Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $37.50.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.